BCDA_OUT_1 [2025-04-28 12:25:07 -0400] 6190 Bytes | 1657 tokens | Cum: 1657 tkns (20.71% of 8k)
==========================================================================

Booyah, my friends! It's already 12:25 PM on Mon Apr 28, 2025, and I've got my eyes locked on BioCardia (BCDA), pushing up to $2.42 from $1.97. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: BioCardia (BCDA)
IPO: 1996-11-13 (28 Years Ago)
Market Cap: $8,008,746
Shares Outstanding: 4,680,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Here’s a list of headlines for BioCardia:

Apr-16-25 05:45AM - DSMB recommends continuation of BioCardias cell therapy trial for heart failure
Apr-15-25 08:30AM - BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial
Apr-14-25 06:52AM - Emory begins enrolment for BioCardias trial of ischemic heart failure therapy
Apr-11-25 09:15AM - BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
Apr-01-25 08:24AM - Q4 2024 BioCardia Inc Earnings Call
Apr-01-25 08:24AM 03:03AM - BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...
Mar-31-25 11:32PM - ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains
Mar-31-25 11:32PM 11:30PM - BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript
Mar-31-25 11:32PM 01:39PM - BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
Mar-31-25 11:32PM 08:00AM - Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
Mar-26-25 04:30PM - BioCardia Reports 2024 Business Highlights and Financial Results
Mar-25-25 09:05AM - What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings
Mar-21-25 08:30AM - BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
Mar-10-25 09:15AM - BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System
Feb-27-25 09:15AM - BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
Feb-13-25 08:30AM - BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)
Jan-31-25 07:16AM - BioCardia upgraded to Buy from Neutral at Alliance Global Partners
Jan-27-25 09:15AM - BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
Dec-17-24 07:00AM - BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family
Dec-04-24 08:30AM - BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
Nov-14-24 02:13AM - BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...
Nov-13-24 04:05PM - BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-08-21T11:00:00Z - FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
B2 - 2024-06-07T11:00:00Z - BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
B3 - 2024-05-21T21:00:00Z - BioCardia Announces Reverse Stock Split
B4 - 2024-05-14T20:02:00Z - BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
B5 - 2024-05-01T11:00:00Z - BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
B6 - 2024-03-27T20:00:00Z - BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for BioCardia (BCDA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

BCDA_OUT_3 [2025-04-28 12:25:08 -0400] 995 Bytes | 277 tokens | Cum: 1936 tkns (24.20% of 8k)
==========================================================================

Showing B5 (chunk 1 of 1): B5:
**BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/01/2873082/0/en/BioCardia-s-CardiAMP-Cell-Therapy-Chronic-Myocardial-Ischemia-Trial-Results-Show-Patient-Benefits-in-Important-Outcomes.htmlSUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_5 [2025-04-28 12:25:09 -0400] 912 Bytes | 268 tokens | Cum: 2206 tkns (27.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T13:00:28Z - Friday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com...
A2 - 2025-04-28T13:02:12Z - Friday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com...
A3 - 2025-04-28T13:02:12Z - Friday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com...
A4 - 2025-04-26T01:42:06Z - Biocardia CFO David McClung buys $24,999 in company stock By Investing.com...
A5 - 2025-04-26T01:42:06Z - Biocardia CFO David McClung buys $24,999 in company stock By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BCDA_OUT_7 [2025-04-28 12:25:09 -0400] 1181 Bytes | 314 tokens | Cum: 2522 tkns (31.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Friday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com**Date: 2025-04-28Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/stock-market-news/fridays-insider-activity-top-buys-and-sells-in-us-stocks-93CH-4007471This article summarizes the most significant insider buying and selling activities reported for US stocks on Friday, April 25, 2025.

Top Insider Buys:

BioCardia, Inc. (NASDAQ:BCDA) saw a substantial insider purchase as Chief Financial Officer David McClung acquired 13,123 shares at $1.905 per share, totaling approximately $24,999. This transaction was part of a private placement and included warrants for an additional 13,123 shares at the same price. McClung's purchase is notable as the stock trades near its 52-week low of $1.62, having declined 65% over the past year. Following this transac

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_9 [2025-04-28 12:25:10 -0400] 1181 Bytes | 315 tokens | Cum: 2839 tkns (35.49% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): tion, McClung now holds 43,131 shares of BioCardia common stock directly.

LKQ Corp (NASDAQ:LKQ) President and CEO Jude Justin L made a significant acquisition, purchasing 2,708 shares at an average price of $36.9934 per share, for a total transaction value of $100,178. This buy comes as the stock has recently experienced an 11% decline over the past week and is trading near its 52-week low. Justin now holds 280,777.424 shares directly. LKQ Corp, with a market capitalization of $9.59 billion and a P/E ratio of 13.8, currently offers a 3.22% dividend yield.

Neogen Corp (NASDAQ:NEOG) director William T. Boehm acquired 5,000 shares at an average price of $5.235 per share, resulting in a total purchase value of $26,175. This transaction increased Boehm's holdings to 36,214 shares. The purchase comes as Neogen's stock shows signs of recovery, posting an 18% gain over the past week despite be

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_11 [2025-04-28 12:25:11 -0400] 1181 Bytes | 303 tokens | Cum: 3144 tkns (39.30% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): ing down 62% over the last six months. The company's current market capitalization stands at $1.1 billion.

Top Insider Sells:

Carriage Services Inc . (NYSE:CSV) CEO Carlos Quezada sold 1,363 shares at a weighted average price of $40.12 per share, totaling approximately $54,683. This transaction was conducted automatically under a pre-established Rule 10b5-1 trading plan. The sale comes as the stock shows strong momentum, with a 61% return over the past year. Following this sale, Quezada holds 110,077 shares of Carriage Services' common stock.

Penumbra Inc (NYSE:PEN) Executive Vice President, General Counsel & Secretary Johanna Roberts sold 600 shares at a weighted average price of $300.01 per share, amounting to a total sale value of $180,006. This transaction was part of a Rule 10b5-1 trading plan. Roberts also exercised stock options to acquire 600 shares at a price of $22.04 per sh

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_13 [2025-04-28 12:25:12 -0400] 1181 Bytes | 286 tokens | Cum: 3432 tkns (42.90% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): are. Following these transactions, Roberts holds 66,159 shares of Penumbra's common stock.

SentinelOne , Inc. (NYSE:S) President and CEO Tomer Weingarten (NYSE:WRI) sold 60,864 shares at a weighted average price of $17.8233 per share, generating approximately $1.08 million. The shares were sold under a Rule 10b5-1 trading plan. Weingarten also converted Class B common stock to Class A common stock, acquiring 60,864 shares at a conversion price of $9.74 per share. Following these transactions, Weingarten holds 1,581,396 shares of Class A common stock directly.

Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company's prospects. While insider transactions alone should not be the sole basis for investment decisions, they can offer clues about management's confidence in the company's future performance. However, it's importa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_15 [2025-04-28 12:25:12 -0400] 434 Bytes | 107 tokens | Cum: 3541 tkns (44.26% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): nt to consider these transactions in the context of broader market trends, company fundamentals, and individual circumstances of the insiders involved.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_17 [2025-04-28 12:25:13 -0400] 541 Bytes | 140 tokens | Cum: 3683 tkns (46.04% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S7 - 2025-04-15 8-K Item 7.01 Regulation FD Disclosure.

On April 15, 2025, BioCardia, Inc. issued a press release announcing that the independent Data Safety Monitoring Board for the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial, which conducted a planned review of t...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BCDA_OUT_19 [2025-04-28 12:25:14 -0400] 974 Bytes | 240 tokens | Cum: 3925 tkns (49.06% of 8k)
==========================================================================

Showing S7 (chunk 1 of 1): S7:
Item 7.01 Regulation FD Disclosure.

On April 15, 2025, BioCardia, Inc. issued a press release announcing that the independent Data Safety Monitoring Board for the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial, which conducted a planned review of the 30-day safety data from the roll-in 20 million cell dosing cohort in the trial, recommended that the study continue as designed. There have been no treatment emergent major adverse cardiac events observed, nor has there been any clinical evidence of immune reactions to the allogeneic cells implanted.

A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCDA_OUT_21 [2025-04-28 12:25:22 -0400] 7338 Bytes | 2096 tokens | Cum: 6023 tkns (75.29% of 8k)
==========================================================================

This is our set of metrics for BioCardia.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 247,401 | Perf Month: -8.96% | Option/Short: No / Yes | Sales Y/Y TTM: -87.84% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 66.47K | Perf Quarter: 7.49% | Short Float: 1.08% | ROE: -737.89% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 8.51 | Index: - | Short Ratio: 0.60 | ROI: -566.36% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 60.63 | Market Cap: 11.42M | Short Interest: 0.04M | Sales Surprise: 11.11% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.20 | Shs Outstand: 4.60M | Beta: 0.99 | EPS Surprise: 90.40% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 20.76% | Shs Float: 3.69M | Sales Q/Q: -100.00% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: 5.66% | Inst Own: 2.67% | Sales past 5Y: 80.21% | Earnings: Mar 26 AMC |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -1.64% | Insider Own: 21.10% | Employees: 20 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 39.67% | Insider Trans: 50.99% | Debt/Eq: 1.13 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by BioCardia officers or majority shareholders (if available).

Inside Trans: BioCardia, Inc. (BCDA) by Altman Peter (President and CEO) on 2025-04-23
- Common Stock: 26246 shares at $1.905 (D)
- Warrant (right to buy): 26246 shares at $N/A (D)

Inside Trans: BioCardia, Inc. (BCDA) by STERTZER SIMON H (Unknown Title) on 2025-04-23
- Common Stock: 104986 shares at $1.905 (I)
- Warrant (right to buy): 104986 shares at $N/A (I)

Inside Trans: BioCardia, Inc. (BCDA) by Blank Andrew Scott (Unknown Title) on 2025-04-23
- Common Stock: 131233 shares at $1.905 (I)
- Warrant (right to buy): 131233 shares at $N/A (I)

Inside Trans: BioCardia, Inc. (BCDA) by Facteau Bill (Unknown Title) on 2025-04-23
- Common Stock: 13123 shares at $1.905 (D)
- Warrant (right to buy): 13123 shares at $N/A (D)

Inside Trans: BioCardia, Inc. (BCDA) by McClung David (Chief Financial Officer) on 2025-04-23
- Common Stock: 13123 shares at $1.905 (D)
- Warrant (right to buy): 13123 shares at $N/A (D)

Inside Trans: BioCardia, Inc. (BCDA) by Altman Peter (President and CEO) on 2025-04-15
- Common Stock: 100 shares at $2.14 (D)

Inside Trans: BioCardia, Inc. (BCDA) by Altman Peter (President and CEO) on 2025-04-10
- Common Stock: 300 shares at $1.99 (D)
- Common Stock: 300 shares at $2.03 (D)

Inside Trans: BioCardia, Inc. (BCDA) by Altman Peter (President and CEO) on 2025-04-07
- Common Stock: 500 shares at $1.96 (D)

Inside Trans: BioCardia, Inc. (BCDA) by Altman Peter (President and CEO) on 2025-04-04
- Common Stock: 800 shares at $2.04 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 58000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -7946000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.415
Average Volume: 98245.05
30-Day High: 2.54
30-Day Low: 1.747

[Detailed Financials: TTM 2024]
- Total Assets: $3,724,000.00
- Total Liabilities: $2,887,000.00
- Total Equity: $837,000.00
- Current Assets: $2,622,000.00
- Current Liabilities: $2,321,000.00

[Income Statement: TTM 2024]
- Revenue: $58,000.00
- Net Income: $-7,946,000.00
- Gross Profit: N/A
- Operating Income: $-8,001,000.00
- Earnings Per Share (EPS): -2.9

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,268,000.00

[Detailed Financials: FY 2024]
- Total Assets: $3,724,000.00
- Total Liabilities: $2,887,000.00
- Total Equity: $837,000.00
- Current Assets: $2,622,000.00
- Current Liabilities: $2,321,000.00

[Income Statement: FY 2024]
- Revenue: $58,000.00
- Net Income: $-7,946,000.00
- Gross Profit: N/A
- Operating Income: $-8,001,000.00
- Earnings Per Share (EPS): -2.9

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,268,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of BioCardia (BCDA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about BioCardia.

2) MARKET_SCORE[]
This conversation was initiated because BCDA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for BCDA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, BCDA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect BCDA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of BioCardia.

11) ETHICAL_RATING[]
Rate BioCardia’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of BioCardia.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

BCDA_IN_23 [2025-04-28 12:25:22 -0400] 126 Bytes | 29 tokens | Cum: 6289 tkns (78.61% of 8k)
==========================================================================

====================================
[2025-04-28 12:25:22] # Analysis Completed
Elapsed Time: 16.54 seconds